Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

20.45
+0.27001.34%
Post-market: 20.450.00000.00%16:56 EST
Volume:2.11M
Turnover:42.96M
Market Cap:1.97B
PE:-3.51
High:20.62
Open:20.00
Low:19.63
Close:20.18
52wk High:45.00
52wk Low:18.41
Shares:96.48M
Float Shares:92.79M
Volume Ratio:0.71
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-412.99%
ROA:-24.92%
PB:215.41
PE(LYR):-3.51

Loading ...

Ultragenyx FY 2025 Evkeeza product sales jump to USD 59 million (+84%)

Reuters
·
57 mins ago

Ultragenyx Lawsuits Add Legal Overhang To Setrusumab Setback And 2027 Goals

Simply Wall St.
·
5 hours ago

Ultragenyx Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Yesterday

Ultragenyx Faces Securities Class Action After Stock Plunge

Reuters
·
Yesterday

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Feb 17

Ultragenyx price target lowered to $37 from $39 at Evercore ISI

TIPRANKS
·
Feb 17

Ultragenyx Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 17

Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright

TIPRANKS
·
Feb 17

Ultragenyx Faces Securities Class Action Over Misleading Study Claims

Reuters
·
Feb 16

Is Ultragenyx Pharmaceutical (RARE) Mispriced After Steep Multi‑Year Share Price Declines?

Simply Wall St.
·
Feb 16

Ultragenyx Faces Securities Class Action Over Alleged Misleading Statements

Reuters
·
Feb 15

Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials

Reuters
·
Feb 14

Why Is Ultragenyx Stock Sinking Friday?

Benzinga
·
Feb 14

Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures

TIPRANKS
·
Feb 14

Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Feb 13

Ultragenyx price target lowered to $61 from $71 at Goldman Sachs

TIPRANKS
·
Feb 13

Stock Track | Ultragenyx Pharmaceutical Plummets 8.34% Intraday Following Multiple Analyst Price Target Cuts

Stock Track
·
Feb 13

Stock Track | Ultragenyx Pharmaceutical Plunges 7.28% in Pre-market After Multiple Analyst Price Target Cuts

Stock Track
·
Feb 13

Ultragenyx Pharmaceutical Inc : TD Cowen Cuts Target Price to $49 From $75

THOMSON REUTERS
·
Feb 13

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Feb 13